Literature DB >> 22995330

Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).

Julia Turbiner Geyer1, Shalini Verma, Susan Mathew, Y Lynn Wang, Joelle Racchumi, Rosanny Espinal-Witter, Shivakumar Subramaniyam, Daniel M Knowles, Attilio Orazi.   

Abstract

The current World Health Organization classification considers myelodysplastic syndrome with isolated del(5q) a distinct entity owing to its characteristic clinical and pathologic features. Recently, several studies have examined survival, leukemic transformation, and various prognostic factors in these patients. However, there is a lack of detailed comparative pathologic analysis of myelodysplastic syndrome cases in which del(5q) is present in association with additional cytogenetic abnormalities. We studied 26 cases of myelodysplastic syndrome at initial diagnosis with 5q- alone, 5q- plus 1 additional abnormality, and 5q- as part of a complex karyotype. Four of 17 patients had evidence of JAK2 V617F mutation. In contrast to cases of myelodysplastic syndrome with isolated 5q-, patients with additional abnormalities had normal mean corpuscular volume and decreased platelet counts (P < .001). Based on bone marrow examination, they were significantly more likely to have increased cellularity, trilineage dysplasia, lower proportion of small hypolobated megakaryocytes, higher number of blasts, and fibrosis. The presence of these morphologic features can be used to distinguish these more aggressive cases from those with myelodysplastic syndrome with isolated 5q- and a more benign clinical course.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22995330     DOI: 10.1016/j.humpath.2012.05.022

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  3 in total

1.  Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.

Authors:  Sa A Wang; Robert P Hasserjian; Patricia S Fox; Heesun J Rogers; Julia T Geyer; Devon Chabot-Richards; Elizabeth Weinzierl; Joseph Hatem; Jesse Jaso; Rashmi Kanagal-Shamanna; Francesco C Stingo; Keyur P Patel; Meenakshi Mehrotra; Carlos Bueso-Ramos; Ken H Young; Courtney D Dinardo; Srdan Verstovsek; Ramon V Tiu; Adam Bagg; Eric D Hsi; Daniel A Arber; Kathryn Foucar; Raja Luthra; Attilio Orazi
Journal:  Blood       Date:  2014-03-13       Impact factor: 22.113

2.  Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.

Authors:  Thomas Walenda; Thomas Stiehl; Hanna Braun; Julia Fröbel; Anthony D Ho; Thomas Schroeder; Tamme W Goecke; Björn Rath; Ulrich Germing; Anna Marciniak-Czochra; Wolfgang Wagner
Journal:  PLoS Comput Biol       Date:  2014-04-24       Impact factor: 4.475

Review 3.  Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy.

Authors:  Pellegrino Musto; Vittorio Simeon; Roberto Guariglia; Gabriella Bianchino; Vitina Grieco; Filomena Nozza; Francesco La Rocca; Gioacchino Marziano; Anna Vittoria Lalinga; Emiliano Fabiani; Maria Teresa Voso; Patrizia Scaravaglio; Cristina Mecucci; Giovanni D'Arena
Journal:  Onco Targets Ther       Date:  2014-06-13       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.